Open AccessRole of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
Author(s) -
Deep Dutta,
Ritu Jaisani,
Deepak Khandelwal,
Soumitra Ghosh,
Rajiv Malhotra,
Sanjay Kalra
Publication year - 2019
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_185_19
Subject(s) - medicine , metformin , orlistat , prediabetes , glycemic , quartile , weight loss , pioglitazone , diabetes mellitus , endocrinology , gastroenterology , insulin , type 2 diabetes , obesity , confidence interval
This study evaluated the real-world weight loss and glycemic outcomes of multidrug therapy (MDT) according to various combinations of metformin, sodium-glucose cotransporter -2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor analogs (GLP1a), and orlistat in diabesity.